Literature DB >> 26511742

Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027.

Larry K Kociolek1, Dale N Gerding2.   

Abstract

Clostridium difficile strain BI/NAP1/027 is associated with increased C. difficile infection (CDI) rates and severity, and the efficacy of some CDI therapies may be strain dependent. Although cultured C. difficile isolates can be reliably subtyped by various methods, the long turnaround times, high cost, and limited availability of strain typing preclude their routine use. Nucleic acid amplification tests identify BI/NAP1/027 rapidly from stool, but the emergence of closely related strains compromises test specificity. Although detection of epidemiologically significant pathogens is generally useful for infection control programs, specific data supporting use of rapid detection of BI/NAP1/027 as an infection control tool are still awaited.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26511742      PMCID: PMC4702757          DOI: 10.1128/JCM.02340-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Differential immunodetection of toxin B from highly virulent Clostridium difficile BI/NAP-1/027.

Authors:  Nira R Pollock; Linan Song; Mingwei Zhao; David C Duffy; Xinhua Chen; Susan P Sambol; Dale N Gerding; Ciarán P Kelly
Journal:  J Clin Microbiol       Date:  2015-02-25       Impact factor: 5.948

2.  Pediatric Clostridium difficile infection: 6-year active surveillance in a defined patient population.

Authors:  Nicole Le Saux; Denise Gravel; Michael R Mulvey; Judy Dennis; Abdool S Yasseen; Nicholas Barrowman; Jennifer Bowes
Journal:  Infect Control Hosp Epidemiol       Date:  2014-05-19       Impact factor: 3.254

3.  Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study.

Authors:  Larry K Kociolek; Sameer J Patel; Stanford T Shulman; Dale N Gerding
Journal:  Infect Control Hosp Epidemiol       Date:  2015-04       Impact factor: 3.254

4.  NAP1 strain type predicts outcomes from Clostridium difficile infection.

Authors:  Isaac See; Yi Mu; Jessica Cohen; Zintars G Beldavs; Lisa G Winston; Ghinwa Dumyati; Stacy Holzbauer; John Dunn; Monica M Farley; Carol Lyons; Helen Johnston; Erin Phipps; Rebecca Perlmutter; Lydia Anderson; Dale N Gerding; Fernanda C Lessa
Journal:  Clin Infect Dis       Date:  2014-03-05       Impact factor: 9.079

5.  Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.

Authors:  Dale N Gerding; Thomas Meyer; Christine Lee; Stuart H Cohen; Uma K Murthy; Andre Poirier; Trevor C Van Schooneveld; Darrell S Pardi; Antonio Ramos; Michelle A Barron; Hongzi Chen; Stephen Villano
Journal:  JAMA       Date:  2015-05-05       Impact factor: 56.272

6.  Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study.

Authors:  Yanjiao Zhou; Carey-Ann D Burnham; Tiffany Hink; Lei Chen; Nurmohammad Shaikh; Aye Wollam; Erica Sodergren; George M Weinstock; Phillip I Tarr; Erik R Dubberke
Journal:  J Clin Microbiol       Date:  2014-10-01       Impact factor: 5.948

7.  Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.

Authors:  T Scardina; L Labuszewski; S M Pacheco; W Adams; P Schreckenberger; S Johnson
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03       Impact factor: 3.254

8.  Burden of Clostridium difficile infection in the United States.

Authors:  Fernanda C Lessa; Yi Mu; Wendy M Bamberg; Zintars G Beldavs; Ghinwa K Dumyati; John R Dunn; Monica M Farley; Stacy M Holzbauer; James I Meek; Erin C Phipps; Lucy E Wilson; Lisa G Winston; Jessica A Cohen; Brandi M Limbago; Scott K Fridkin; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

9.  Clostridium difficile infection among children across diverse US geographic locations.

Authors:  Joyanna M Wendt; Jessica A Cohen; Yi Mu; Ghinwa K Dumyati; John R Dunn; Stacy M Holzbauer; Lisa G Winston; Helen L Johnston; James I Meek; Monica M Farley; Lucy E Wilson; Erin C Phipps; Zintars G Beldavs; Dale N Gerding; L Clifford McDonald; Carolyn V Gould; Fernanda C Lessa
Journal:  Pediatrics       Date:  2014-03-03       Impact factor: 7.124

10.  Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain.

Authors:  Sze K Lim; Rhonda L Stuart; Kate E Mackin; Glen P Carter; Despina Kotsanas; Michelle J Francis; Marion Easton; Karolina Dimovski; Briony Elliott; Thomas V Riley; Geoff Hogg; Eldho Paul; Tony M Korman; Torsten Seemann; Timothy P Stinear; Dena Lyras; Grant A Jenkin
Journal:  Clin Infect Dis       Date:  2014-04-04       Impact factor: 9.079

View more
  5 in total

1.  Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.

Authors:  Larry K Kociolek; Dale N Gerding; James R Osmolski; Sameer J Patel; David R Snydman; Laura A McDermott; David W Hecht
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology.

Authors:  Johanna Sandlund; Amelita Bartolome; Anna Almazan; Stanley Tam; Sheryl Biscocho; Salina Abusali; Jeffrey J Bishop; Niamh Nolan; Joel Estis; John Todd; Stephen Young; Fiona Senchyna; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

3.  A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection.

Authors:  Chris A Gentry; Stephanie E Giancola; Sharanjeet Thind; George Kurdgelashvili; Grant H Skrepnek; Riley J Williams
Journal:  Open Forum Infect Dis       Date:  2017-11-02       Impact factor: 3.835

4.  Equivalent Performance of the Cobas® Cdiff Test for Use on the Cobas® Liat® System and the Cobas® 4800 System.

Authors:  Sachin K Garg; Kyle Lu; John Duncan; Lance R Peterson; Oliver Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-12-05

5.  Detection of clostridium difficile antigen and toxin in stool specimens: Comparison of the C. difficile quik chek complete enzyme immunoassay and GeneXpert C. difficile polymerase chain reaction assay.

Authors:  Abiola C Senok; Kamel M Aldosari; Rayan A Alowaisheq; Othman A Abid; Khalid A Alsuhaibani; Mohammad A Khan; Ali M Somily
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.